Moleculin Biotech CS
(MBRX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,915 | -29,025 | -22,255 | -13,644 | -6,867 |
| Depreciation Amortization | 30 | 130 | 98 | 66 | 32 |
| Other Working Capital | 526 | 224 | 1,122 | 410 | 1,573 |
| Other Operating Activity | 1,342 | 1,032 | 652 | 362 | 457 |
| Operating Cash Flow | $-6,017 | $-27,639 | $-20,383 | $-12,806 | $-4,805 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -67 | -67 | -67 | -6 |
| Investing Cash Flow | $N/A | $-67 | $-67 | $-67 | $-6 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 141 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 0 | -23 | -23 | -12 | 0 |
| Financing Cash Flow | $141 | $-23 | $-23 | $-12 | $N/A |
| Exchange Rate Effect | -4 | -29 | -38 | -19 | 12 |
| Beginning Cash Position | 43,145 | 70,903 | 70,903 | 70,903 | 70,903 |
| End Cash Position | 37,265 | 43,145 | 50,392 | 57,999 | 66,104 |
| Net Cash Flow | $-5,880 | $-27,758 | $-20,511 | $-12,904 | $-4,799 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,017 | -27,639 | -20,383 | -12,806 | -4,805 |
| Capital Expenditure | N/A | -67 | -67 | -67 | -6 |
| Free Cash Flow | -6,017 | -27,706 | -20,450 | -12,873 | -4,811 |